Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3058% above fair value
$0.99−0.12 (-10.78%)
Close on Nov 12, 2026Market cap $250.45MP/E –Yield –
Lineage Cell Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lineage Cell Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$29.62M. For fiscal 2025 it was -$35.92M. The highest annual figure on record is -$20.89M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$35.92M | – |
| FY2024 | Dec 31, 2024 | -$20.89M | – |
| FY2023 | Dec 31, 2023 | -$24.17M | – |
| FY2022 | Dec 31, 2022 | -$21.94M | – |
| FY2021 | Dec 31, 2021 | -$48.55M | – |
| FY2020 | Dec 31, 2020 | -$25.62M | – |
| FY2019 | Dec 31, 2019 | -$37.87M | – |
| FY2018 | Dec 31, 2018 | -$40.71M | – |
| FY2017 | Dec 31, 2017 | -$37.96M | – |
| FY2016 | Dec 31, 2016 | -$57.79M | – |
| FY2015 | Dec 31, 2015 | -$64.73M | – |
| FY2014 | Dec 31, 2014 | -$49.63M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$7.11M | – |
| Q2 FY2026 | Jun 30, 2026 | -$8.74M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.41M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.36M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.34M | – |
| Q4 FY2024 | Dec 31, 2024 | -$4.96M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.70M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.73M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.51M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.22M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.56M | -104.7% |
| Q2 FY2023 | Jun 30, 2023 | -$4.89M | -103.4% |
| Q1 FY2023 | Mar 31, 2023 | -$6.50M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.50M | – |
| Q3 FY2022 | Sep 30, 2022 | $139.75M | – |
| Q2 FY2022 | Jun 30, 2022 | $141.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.92M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.88M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.68M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.23M | – |
| Q4 FY2019 | Dec 31, 2019 | -$6.64M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.58M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.49M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.84M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.10M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.87M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.91M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.29M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.26M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.36M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.07M | – |
See a number that looks wrong?